In Vitro Activities of Ceftazidime-Avibactam and Comparator Antimicrobial Agents Tested against ESBL Producing Urinary E. coli Isolates
Autor: | Dilara Ogunc, Estelle Caine, Dilek Colak, Filiz Gunseren, Emre Yildiz, Kubra Kasaroglu, Gözde Öngüt, Betil Özhak, Özlem Koyuncu Özyurt, Özge Turhan |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
esbl
business.industry ceftazidime-avibactam Urinary system lcsh:QR1-502 Esbl production Pharmaceutical Science biochemical phenomena metabolism and nutrition Ceftazidime/avibactam Antimicrobial bacterial infections and mycoses lcsh:Microbiology In vitro Microbiology Complementary and alternative medicine in vitro susceptibility test Medicine Pharmacology (medical) urinary tract infections Ceftazidime-avibactam ESBL Urinary tract infections in vitro business medicine.drug |
Zdroj: | Volume: 09, Issue: 03 112-115 Journal of Microbiology and Infectious Diseases Journal of Microbiology and Infectious Diseases, Vol 09, Iss 03, Pp 112-115 (2019) |
ISSN: | 2146-3158 2146-9369 |
Popis: | Objectives: Urinary tract infections (UTIs) remain one of the most common infections for antibiotic prescription. Increased resistance to antibiotics currently used to treat these infections may lead to significant problems. Extended spectrum beta-lactamase (ESBL) production in organisms causing UTIs are often responsible for the increase in resistance. The aim of this study was to investigate the in vitro antimicrobial susceptibility of ESBL producing community acquired urinary E. coli isolates to Ceftazidime/Avibactam (CAZ/AVI) and other antimicrobial agents using disk diffusion method. Methods: Between 2016 and 2017, a total of 100 ESBL producing E. coli urine isolates were collected from outpatients who had no history of hospitalization in the last three months in Akdeniz University Hospital. All isolates were tested for in vitro susceptibility to the CAZ/AVI and other antimicrobial agents using disk diffusion method. Results: No CAZ/AVI and carbapenem resistance were observed. Resistance rates to other antimicrobial agents were as follows: ampicillin 100%, amoxicillin/clavulanate 85%, cefotaxime 98%, ceftazidime 89%, cefepime 82%, gentamicin 41%, ciprofloxacin 65%, levofloxacin 39%, fosfomycin 3%, nitrofurantoin 2%, trimethoprim/sulfamethoxazole 72% and Piperacillin/Tazobactam 41%. Conclusions: Our results showed that ceftazidime / avibactam, carbapenems, nitrofurantoin and fosfomycin may be among the first line treatment options in the empirical therapy. In selected patients, CAZ/AVI could be an option for the treatment of UTI caused by ESBL producing E.coli which may reduce the use of carbapenems. J Microbiol Infect Dis 2019; 9(2):112-115. |
Databáze: | OpenAIRE |
Externí odkaz: |